The prognostic impact of SF3B1 mutations may vary among different MDS entities, reflecting differences in replicative stress-driven tumorigenesis or differential genomic stability and cell viability of different cell types after treatment (58, 98, 99). The gene discussed is SF3B1; the disease is myelodysplastic syndrome.